drugset / Trial / NCT01558219
Second-line Chemotherapy in Castration Resistant Prostate Cancer
Phase 2
Completed
60 enrolled
Tampere University Hospital
Helsinki University Central Hospital · collabKuopio University Hospital · collabSeinajoki Central Hospital · collabTurku University Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is designed to evaluate the safety of biweekly cabazitaxel for the treatment of metastatic castration resistant prostate cancer (mCRPC) patients previously treated with docetaxel containing regimen. The primary endpoint is safety. Secondary endpoints include time to treatment failure, response rate, overall survival and quality of life.
Timeline
- Start
- 2011-11
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabazitaxel | Other / unclassified | 16 mg/m2 | Intravenous |